• Dewpoint will present two posters at AACR 

• Condensate modulators (c-mods) demonstrate robust anti-tumor effects across multiple types of cancer 

• C-mods modulate the oncogenic function of historically undruggable targets MYC and beta catenin  

Boston, Massachusetts, March 26, 2025 – Dewpoint Therapeutics Inc. – the leading biotechnology company in transforming condensate biology into medicine, announced today the publication of two abstracts accepted for presentation at the American Association of Cancer Research (AACR) Annual Meeting, taking place in Chicago, IL, between April 25-30, 2025.

“We are excited to share promising results from our oncology pipeline, that demonstrate profound pre-clinical effects produced by condensate modulating compounds (c-mods). These c-mods alter the oncogenic functions of the ‘holy grail’ targets MYC and beta catenin through novel mechanisms of action that leverage our unique expertise in condensate biology”, said Dr. Ameet Nathwani, Dewpoint’s Chief Executive Officer.

Dewpoint will present the following two posters: 

About Dewpoint Therapeutics   

Dewpoint is the leading biotech company in the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. The realization that a vast range of conditions are regulated by or arise from the dysfunction of condensates has provided new possibilities for modulating the function of high-value targets previously deemed ‘undruggable,’ opening unexplored avenues to identify hundreds of novel therapeutic targets. Dewpoint’s proprietary AI/ML-powered state-of-the-art platform underlies a drug discovery pipeline that spans multiple therapeutic areas, including oncology, neurodegenerative, cardiopulmonary, and metabolic diseases. Through collaborations with Bayer, Novo Nordisk, Evotec, and Mitsubishi Tanabe Pharma Corporation, Dewpoint pushes the boundaries to accelerate the translation of condensate biology into medicine for patients suffering from difficult-to-treat diseases. Learn more at Dewpointx.com and follow us on  LinkedIn. 

About Condensates   
Condensates are membraneless organelles that form dynamically throughout the cell via a process called phase separation. These subcellular compartments organize and concentrate molecules within cells to enable a diversity of key biochemical processes. The dysregulation of biomolecular condensates has been observed in many diseases, including cancer, diabetes, cardiopulmonary and neurological disorders. Condensate-modulating drugs (c-mods) potentially provide novel therapeutic options for complex diseases and historically undruggable targets. Learn more about condensate science at Condensates.com.  

The post Dewpoint Therapeutics Announces Upcoming Presentations at AACR 2025  appeared first on Dewpoint Therapeutics.

• Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel condensate modulating mechanism of action for the treatment of Wnt-driven cancers 

• DPTX3496 shows robust tumor regression and stasis in pre-clinical animal models of colorectal, breast and lung cancer 

• DPTX3496 is currently in IND-enabling studies and IND filing is planned for the second half of 2025  

Boston, Massachusetts, January 29, 2025 – Dewpoint Therapeutics Inc. – the leading biotechnology company in transforming condensate biology into medicine, announced today the nomination of a second development candidate (DC), DPTX3496. DPTX3496 is an oral, small molecule condensate modulator (c-mod) targeting beta catenin to address Wnt-driven colorectal cancer (CRC), triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC). Based on the preclinical data package, IND-enabling studies have commenced for DPTX3496 with an IND filing planned for the second half of this year.  

Dysregulation of the Wnt pathway, with constitutive activation of beta catenin-driven oncogenic transcription, is a shared root cause of uncontrolled cell proliferation across multiple types of cancers. DPTX3496, which was discovered and optimized using Dewpoint’s proprietary platform, inhibits beta catenin’s aberrant transcriptional activity by sequestering beta catenin into nuclear condensate depots. This sequestration takes advantage of a condensate-mediated mechanism of action to selectively drive apoptosis of cancer cells with excessive beta catenin/Wnt signaling. 

DPTX3496 has demonstrated tumor regression and stasis in a broad panel of Wnt-driven tumors, including patient-derived xenograft (PDX) mouse models of CRC, TNBC, and NSCLC, along with good tolerability and minimal body weight loss. Additionally, Dewpoint has developed a suite of novel biomarker assays to monitor modulation of beta catenin activity, which will be translated to the clinic to monitor target engagement and modulation. DPTX3496 shows down-regulation of beta catenin-driven gene transcription and Wnt pathway activity in vivo, and plasma protein profiling demonstrates modulation of systemic disease-associated beta catenin target genes. 

Over the past three months, Dewpoint has nominated two DCs that target the beta catenin/Wnt pathway – DPTX3186 and DPTX3496. The two DCs are of two distinct chemotypes. Both beta catenin c-mods are orally bioavailable small molecules that selectively inhibit the oncogenic function of beta catenin through the novel condensate depot-forming mechanism. “We will develop DPTX3186 for the treatment of gastric cancer, and progress DPTX3496 to IND for colorectal, breast, and lung cancers. This tumor-specific development strategy enables us to address significant patient populations with tailored regulatory approaches, focused combinations, and develop custom market-entry strategies given the diverse treatment pathways for each tumor,” said Dr. Ameet Nathwani MD, Chief Executive Officer at Dewpoint. “By generating differentiated and focused clinical data for specific tumor types, our approach enhances the opportunity for competitive differentiation, offers optionality for future co-development and co-commercialization opportunities and provides potential mitigation against future IRA challenges.” 

Additionally, as part of a recently announced strategic collaboration, Dewpoint will leverage ConcertAI’s clinico-genomic data sets and the CARAai™ platform in tandem with Dewpoint’s extensive biomarker suite. Working with ConcertAI will enable Dewpoint to optimize patient stratification of Wnt-driven tumor populations that are mostly likely to respond to the novel beta catenin depot forming c-mod mechanism. Furthermore, IND-enabling packages for both DPTX3186 and DPTX3496 are being generated in collaboration with Evotec, using their INDiGO platform to accelerate IND filing timelines.  

About Dewpoint Therapeutics   

Dewpoint is the leading biotech company in the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. The realization that a vast range of conditions are regulated by or arise from the dysfunction of condensates has provided new possibilities for modulating the function of high-value targets previously deemed ‘undruggable,’ opening unexplored avenues to identify hundreds of novel therapeutic targets. Dewpoint’s proprietary AI/ML-powered state-of-the-art platform underlies a drug discovery pipeline that spans multiple therapeutic areas, including oncology, neurodegenerative, cardiopulmonary, and metabolic diseases. Through collaborations with Bayer, Novo Nordisk, Evotec, and Mitsubishi Tanabe Pharma Corporation, Dewpoint pushes the boundaries to accelerate the translation of condensate biology into medicine for patients suffering from difficult-to-treat diseases. Learn more at Dewpointx.com and follow us on X and LinkedIn. 

About Condensates   
Condensates are membraneless organelles that form dynamically throughout the cell via a process called phase separation. These subcellular compartments organize and concentrate molecules within cells to enable a diversity of key biochemical processes. The dysregulation of biomolecular condensates has been observed in many diseases, including cancer, diabetes, cardiopulmonary and neurological disorders. Condensate-modulating drugs (c-mods) potentially provide novel therapeutic options for complex diseases and historically undruggable targets. Learn more about condensate science at Condensates.com.

The post Dewpoint Therapeutics Announces DPTX3496 as a Development Candidate for the Treatment of Colorectal, Breast, and Lung Cancers  appeared first on Dewpoint Therapeutics.

Poster presented at the SLAS2025 International Conference

> Download the PDF file

The post High throughput platform for ALS drug discovery by using human iPSC-derived motor neurons appeared first on Dewpoint Therapeutics.

Supporting Dewpoint’s novel condensate modulating approach to drug previously ‘undruggable’ therapeutic targets, guided by ConcertAI’s Clinico-Genomic Solutions 

Boston, MA and Cambridge, MA, December 12, 2024 – Dewpoint Therapeutics and ConcertAI announced the first phase of their Translational Oncology partnership, aligned around Dewpoint’s latest drug candidate, DPTX3186.   

Numerous tumor types including colorectal, breast, lung and gastric tumors are driven by an overactive Wnt pathway, due to uncontrolled beta catenin-dependent transcriptional activity.  DPTX3186 is a small molecule condensate modulator (c-mod) that inhibits beta catenin oncogenic function, modulating what has been described as an ‘undruggable’ therapeutic target.  The first phase of the partnership will support DPTX3186 development by optimizing patient stratification through the synergy between Dewpoint’s AI/ML-powered discovery and development platform, and ConcertAI’s clinico-genomic data sets and the CARAai™ platform.  Future phases of the partnership are anticipated to similarly support other candidates in Dewpoint’s oncology pipeline, including a second beta catenin c-mod with indications for other Wnt-driven tumor types, set for investigational new drug (IND) in 2025, and a c-mod for MYC, another ‘undruggable’ oncogene, set for IND in 2026. 

Dewpoint, founded in 2018, focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. Condensates compartmentalize and integrate biochemical processes and their components.  Many diseases are regulated by, or arise from, the dysfunction of condensates. This in turn has provided new possibilities for approaching high-value targets previously deemed ‘undruggable.’ Dewpoint’s proprietary AI/ML-powered discovery and development platform supports a drug discovery pipeline that spans multiple therapeutic areas, including oncology, neurodegenerative, cardiopulmonary, and metabolic diseases. Dewpoint’s pipeline consists of wholly owned and partnered programs. To date, the company has raised $287M through series C and is planning two INDs in 2025. The total value of partnered programs with milestones is over $2 billion.   

ConcertAI, founded in 2018, is the leading multi-modal research-grade Data-as-a-Service (DaaS) and AI Software-as-a-Service (SaaS) company in oncology, providing solutions to almost 50 life science companies and 2,000 healthcare providers and research sites. ConcertAI has also raised in excess of $230 million through series C. ConcertAI’s DaaS and AI SaaS solutions are provided through the CARAai™ platform announced in June of 2023.  CARAai™ is an oncology research and standard-of-care decision augmentation platform partnered with NVIDIA and others.   

“Discovery of new cancer medicines is complex.  The number of new standard-of-care entities approved each year has been growing at an accelerated pace. As patients are exposed to different medicines there can be modifications to their disease and potential resistance to treatment being acquired. By assembling high-depth clinico-molecular datasets with genomic, transcriptomic and clinical depth, the collaborative ConcertAI and Dewpoint team can set a basis for the priority cancers for their new programs and inform the first-in-human and proof-of-concept studies” said Jeff Elton, Ph.D., CEO of ConcertAI.   

Dewpoint is distinctive in both taking a highly innovative approach to the most significant and historically unapproachable targets impacting diseases with the highest unmet needs through condensate biology and building an AI/ML-powered discovery and development platform that assures a steady stream of new targets and drug candidates.  As part of the partnership, ConcertAI will be providing clinico-molecular DaaS capabilities that support modeling and simulation of outcomes of new therapeutics, essentially bridging Dewpoint’s AI/ML-powered discovery and development platform to ConcertAI Translational and Clinical Capabilities.   

“The discovery and selection of DPTX3186, our first development candidate, underscores the merits of a new approach and fresh perspective on the biology of the most devastating diseases. This orally administrable small molecule condensate modulator of beta catenin is a direct product emerging from our proprietary, AI/ML-powered discovery and development platform”, said Ameet Nathwani, M.D., CEO of Dewpoint.  “This program has demonstrated significant activity, including profound tumor regression in preclinical models across multiple Wnt-pathway driven cancers.  Consistent with our data science-enabled approaches and deep partnering culture, we are excited by the prospect that working with ConcertAI may more accurately allow us to prioritize the optimal patient populations and define key characteristics of these first in human trials, resulting in higher quality studies and more meaningful outcomes.”   

The specific terms of the partnership were not disclosed.   

About Dewpoint Therapeutics   

Dewpoint is the leading biotech company in the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. The realization that a vast range of conditions are regulated by or arise from the dysfunction of condensates has provided new possibilities for modulating the function of high-value targets previously deemed ‘undruggable,’ opening unexplored avenues to identify hundreds of novel therapeutic targets. Dewpoint’s proprietary AI/ML-powered state-of-the-art platform underlies a drug discovery pipeline that spans multiple therapeutic areas, including oncology, neurodegenerative, cardiopulmonary, and metabolic diseases. Through collaborations with Bayer, Novo Nordisk, Evotec, and Mitsubishi Tanabe Pharma Corporation, Dewpoint pushes the boundaries to accelerate the translation of condensate biology into medicine for patients suffering from difficult-to-treat diseases. Learn more at Dewpointx.com and follow us on X and LinkedIn. 

About Condensates   
Condensates are membraneless organelles that form dynamically throughout the cell via a process called phase separation. These subcellular compartments organize and concentrate molecules within cells to enable a diversity of key biochemical processes. The dysregulation of biomolecular condensates has been observed in many diseases, including cancer, diabetes, cardiopulmonary and neurological disorders. Condensate-modulating drugs (c-mods) potentially provide novel therapeutic options for complex diseases and historically undruggable targets. Learn more about condensate science at Condensates.com.  

About ConcertAI 
ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARA™ AI technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon® provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT.  CancerLinQ® is an Initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, MA, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at concertai.com. 

The post Dewpoint Therapeutics and ConcertAI Announce the First Phase of their Translational Oncology Partnership  appeared first on Dewpoint Therapeutics.

• Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying pathology of >97% of ALS patients.

• Mitsubishi Tanabe Pharma Corporation obtains an option for a global license to develop and commercialize the novel TDP-43 small molecule condensate modulator.

• Deal valued at up to $480 million- Dewpoint to receive an upfront and additional development and commercial milestone payments, excluding royalties.

BOSTON, Massachusetts, December 4, 2024 – Dewpoint Therapeutics Inc., the leading biotechnology company that develops therapeutics by targeting biomolecular condensates, announced today that it has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC) to advance Dewpoint’s novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS), effective December 1, 2024.

Under the terms of the agreement, Dewpoint will receive an upfront payment and will be eligible for milestone payments based on specified near-term research and development objectives, with a total nominal deal value of up to $480M. Upon reaching these milestones, MTPC will have an exclusive option to license the program and assume responsibility for global clinical development and commercialization. Dewpoint will also receive tiered royalties on net sales.

“We are delighted to collaborate with MTPC in advancing our condensate-modulating approach to address the critical unmet need in the treatment of ALS,” said Ameet Nathwani, MD, CEO of Dewpoint Therapeutics. “This partnership underscores the transformative potential of our small molecule condensate modulator which aims to tackle the underlying pathology of ALS and related neurodegenerative diseases via a novel mechanism of action. Our c-mod was discovered and developed through Dewpoint’s pioneering condensate-targeted platform. MTPC’s unparalleled expertise in ALS, as the developer of one of the few FDA-approved therapies for sporadic ALS, combined with their global clinical capability and expansive patient network, makes them an ideal partner. Together, we are poised to accelerate the clinical development of this innovative program and bring hope to patients facing this devastating disease.”

By leveraging its unique expertise in condensate biology, Dewpoint has discovered a small molecule that addresses the mislocalization of the TAR DNA-binding protein 43 (TDP-43), a critical splicing factor implicated in several neurodegenerative diseases and a key pathological feature present in over 97% of ALS patients. TDP-43 abnormally accumulates in membrane-less cytoplasmic structures, known as biomolecular condensates, leading to neuronal dysfunction in ALS patients.

Using their high-content, high-throughput screening approach, Dewpoint identified a c-mod capable of mitigating these pathological TDP-43 condensates by selectively departitioning TDP-43 and restoring its correct localization into the nucleus, while preserving the normal cellular stress response. By correcting this disease-driving condensate dysfunction (condensatopathy), the treatment restores TDP-43’s normal splicing activity, promotes neuronal health, and improves multiple clinically relevant ALS biomarkers in animal models.

Ameet Nathwani added: “The success we’ve had so far with this c-mod in reversing ALS-associated pathology suggests that this compound may find future applications in other indications which share the TDP-43 condensatopathy.”

“ALS remains a critical area of unmet medical needs and MTPC is committed to addressing it as the leading company in ALS therapeutics.” said Masao Nawano, Ph.D., Vice President, Head of Research Division of MTPC. “There are limited treatment options for ALS patients, particularly those with sporadic ALS, where no known underlying genetic cause has been established. We are excited to join forces with Dewpoint to advance this promising small molecule c-mod that takes advantage of their unique expertise and cutting-edge technologies in condensate biology. Together, we have the potential to deliver meaningful innovations to patients and families affected by this devastating condition. This research collaboration and option agreement strategically represents MTPC’s mission: ‘Creating hope for all facing illness.’ Generating new unique compounds to address unmet medical needs and provide clinical benefits are key values of MTPC.“

Gordon Dyal & Co. served as the exclusive financial advisor to Dewpoint Therapeutics. 

About Condensates

Condensates are membraneless organelles that form dynamically throughout the cell via a process called phase separation. These subcellular compartments organize and concentrate biomolecules within cells to enable a diversity of key biochemical processes. The dysregulation of biomolecular condensates has been observed in many diseases, including cancer, diabetes, cardiovascular, and neurological disorders. Condensate modulators (c-mods) potentially provide novel therapeutic options for complex diseases and historically undruggable targets. Learn more about condensates at Condensates.com.

About Dewpoint Therapeutics

Dewpoint Therapeutics is the leading biotech company in the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. The realization that a vast range of conditions are regulated by or arise from the dysfunction of condensates has provided new possibilities for modulating the function of high-value targets previously deemed ‘undruggable,’ opening unexplored avenues to identify hundreds of novel therapeutic targets. Funded by a syndicate of top VCs, Dewpoint’s proprietary AI-powered platform is built to produce a pipeline of first-in-class drugs spanning therapeutic areas, including oncology, neurodegenerative, cardiopulmonary, and metabolic diseases. Through collaborations with Bayer, Novo Nordisk, Mitsubishi Tanabe Pharma Corporation, and Evotec, Dewpoint pushes the boundaries to accelerate the translation of condensate biology into medicine for patients suffering from difficult-to-treat diseases. Learn more at Dewpointx.com and follow us on X and LinkedIn.

About Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan’s pharmaceutical industry. MTPC sets the MISSION of “Creating hope for all facing illness”. To that end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney, and cancer. MTPC is focusing on “precision medicine” to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety. In addition, MTPC is working to develop “around the pill solutions” to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to https://www.mt-pharma.co.jp/e/

The post Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation Enter Research Collaboration to Advance Small Molecule Condensate Modulator for ALS appeared first on Dewpoint Therapeutics.

The Pharma Letter features a major milestone for Dewpoint Therapeutics – the nomination of our first development candidate, DPTX3186, as a potential therapeutic agent for treatment of Wnt-driven cancers.

Read the article to learn more.

The post Major milestone for Dewpoint with first development candidate announced appeared first on Dewpoint Therapeutics.

• Orally administered small molecule condensate modulators (c-mods) are a novel class of therapeutic agents designed to target condensates to modify disease. 

• DPTX3186 is Dewpoint’s first development candidate inhibiting beta catenin activity through a novel condensate mechanism for the treatment of Wnt-driven cancers. 
   
• DPTX3186 shows significant tumor growth inhibition, stasis, and regression in preclinical models of Wnt-driven cancers. 
   
•  IND anticipated in mid-2025 followed by Phase 1 initiation in 2H 2025. 

BOSTON, Massachusetts, October 28, 2024 – Dewpoint Therapeutics Inc., the leading biotechnology company that develops therapeutics by targeting biomolecular condensates, announced today the nomination of its first development candidate, DPTX3186, an orally administered small molecule condensate modulator (c-mod) inhibiting the oncogenic function of beta catenin, as a potential therapeutic agent for treatment of Wnt-driven cancers. The development candidate was discovered using Dewpoint’s fully automated, AI/ML-enabled state-of-the-art platform and proprietary chemical library. 

Beta catenin is a key transcription factor in the Wnt signaling pathway, which plays a crucial role in various physiological processes in healthy cells^1,2. Aberrant activation of beta catenin, as part of constitutively active transcriptional condensates^3,4,5, is associated with carcinogenesis and tumor progression in colorectal cancer, gastrointestinal cancer, non-small cell lung cancer, breast cancer, liver cancer, and other types of cancers^1,2. Beta catenin is often considered an ‘undruggable’ target, due to the presence of disordered regions and structural features lacking suitable drug binding pockets. Historically, the development of beta catenin therapies has been frequently hindered by toxicity and off-target effects¹.  

DPTX3186 is a small molecule c-mod that acts through a novel mechanism of action to sequester beta catenin into nuclear depot condensates. This sequestration leads to downregulation of beta catenin related genes, resulting in significant tumor cell killing. DPTX3186 demonstrates activity across various beta catenin/Wnt-driven tumor cell types, while exhibiting minimal toxicity in healthy cells. In patient-derived and cell-derived xenograft models it displays significant tumor growth inhibition including regression and tumor stasis.  

“Nominating this development candidate marks a significant milestone in our journey to deliver the first condensate modulating drug to the clinic,” said Ameet Nathwani, CEO of Dewpoint Therapeutics. “The discovery and selection of DPTX3186 for a target considered ‘undruggable’ underscores the transformative potential of our state-of-the-art platform combined with a fresh perspective on the underlying biology, through the lens of condensate science. This approach enabled us to identify and advance a novel class of therapeutic agents to address diseases of high unmet need. To date, DPTX3186 has demonstrated significant activity in preclinical models across multiple types of cancer, high selectivity for tumor cells, and a mechanism of action on the beta catenin/Wnt pathway. To accelerate the development of DPTX3186, we partnered with Evotec. Together, we will leverage Evotec’s INDiGO platform for the rapid and efficient generation of a high-quality IND-enabling package. We anticipate filling the IND in mid-2025, followed by the commencement of Phase 1 clinical trial in the second half of 2025.” 

1. Yu F, Yu C, Li F, et al., Sig Transduct Target Ther. 6, 307 (2021). https://doi.org/10.1038/s41392-021-00701-5  

2. Shang S, Hua F, Hu ZW. Oncotarget. 8(20):33972-33989 (2017). https://doi.org/10.18632/oncotarget.15687

3. Gui T, et al., Targeted perturbation of signaling-driven condensates. Mol. Cell. 83(22):4141-4157 (2023). https://doi.org/10.1016/j.molcel.2023.10.023  

4. Zamudio A, et al., Mol. Cell. 76(5):753-766 (2019). https://doi.org/10.1016/j.molcel.2019.08.016     

5. Boija, A, et al., Cell. 2018 Dec 13;175(7):1842-1855.e16 10.1016/j.cell.2018.10.042 

About Condensates  
Condensates are membraneless organelles that form dynamically throughout the cell via a process called phase separation. These subcellular compartments organize and concentrate molecules within cells to enable a diversity of key biochemical processes. The dysregulation of biomolecular condensates has been observed in many diseases, including cancer, diabetes, and neurological disorders. Condensate-modulating drugs (c-mods) potentially provide novel therapeutic options for complex diseases and historically undruggable targets. Learn more about condensate science at Condensates.com. 

About Dewpoint Therapeutics  
Dewpoint is the leading biotech company in the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. The realization that a vast range of conditions are regulated by or arise from the dysfunction of condensates has provided new possibilities for modulating the function of high-value targets previously deemed ‘undruggable,’ opening unexplored avenues to identify hundreds of novel therapeutic targets. Dewpoint’s proprietary AI/ML-powered state-of-the-art platform underlies a drug discovery pipeline that spans multiple therapeutic areas, including oncology, neurodegenerative, cardiopulmonary, and metabolic diseases. Through collaborations with Bayer, Novo Nordisk, and Evotec, Dewpoint pushes the boundaries to accelerate the translation of condensate biology into medicine for patients suffering from difficult-to-treat diseases. Learn more at Dewpointx.com and follow us on X and LinkedIn. 

The post Dewpoint Therapeutics Announces Nomination of First C-Mod Development Candidate DPTX3186 for Treatment of Wnt-Driven Cancers   appeared first on Dewpoint Therapeutics.

• Bayer obtains global license to develop and commercialize disease-modifying treatment specifically for dilated cardiomyopathy (DCM) patients characterized by specific mutations.
• Post-licensing, companies will continue to collaborate on cardiovascular and renal programs.
• Dewpoint will receive an upfront and additional development and commercial milestone payments amounting to an estimated $424 million, excluding royalties.

Berlin, Germany and Boston, Mass., USA, October 24, 2024 – Bayer has entered into an exclusive licensing agreement with Dewpoint Therapeutics, Inc. for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. This is the first option exercised under the research collaboration between Bayer and Dewpoint Therapeutics, Inc., which began in November 2019. It leverages Dewpoint’s proprietary platform for biomolecular condensates and Bayer’s small molecule R&D capabilities to develop new treatments for cardiovascular and renal diseases.

“One of the biggest challenges in drug discovery lies in tackling the undruggable human proteome,” said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer’s Pharmaceuticals Division. “The emerging paradigm of biomolecular condensates is expanding the traditional drug target space for small molecules by unveiling new targets and new approaches to previously intractable targets. We are excited to be part of this new wave of innovation together with Dewpoint Therapeutics as it is our ambition to provide transformative medicines to cardiovascular patients with the highest unmet needs.”

Dilated cardiomyopathy (DCM) is a heart muscle disease where the ventricles enlarge and struggle to pump blood effectively. The licensed program focuses on an innovative method to address a specific form of DCM linked to mutations that lead to the formation of disease-associated condensates. This form of DCM is a severe condition with significant unmet medical needs, characterized by early onset heart failure and frequent life-threatening arrhythmias.

“We are excited about the novel discoveries made possible by our collaboration with Bayer, which have immense potential to transform the treatment of DCM,” said Ameet Nathwani, CEO of Dewpoint Therapeutics. “The licensing of the first discovery program underscores the scientific validation of our proprietary condensate-based approach, which identifies and targets the underlying condensate drivers of complex diseases. The pre-clinical findings in this program suggest that a condensate-modifying small molecule can reverse the fundamental disease process. We are delighted that Bayer has exercised its option to license this exciting program which will further strengthen our ongoing collaboration to explore innovative treatments for cardiovascular and renal diseases.”

Dewpoint Therapeutics will receive an upfront and additional development and commercial milestone payments amounting to an estimated $424 million, excluding royalties. The ongoing collaboration follows Bayer’s participation in Dewpoint’s January 2019 Series A financing round through Leaps by Bayer, the strategic investment unit of Bayer.

About Condensates
Condensates are membraneless organelles that form dynamically throughout the cell via a process called phase separation. These subcellular compartments organize and concentrate molecules within cells to enable a diversity of key biochemical processes. The dysregulation of biomolecular condensates has been observed in many diseases, including cancer, diabetes, and neurological disorders. Condensate-modifying drugs (c-mods) potentially provide novel therapeutic options for complex diseases and historically undruggable targets.

About Dewpoint Therapeutics
Dewpoint is the leading biotech company in the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. The realization that a vast range of conditions are regulated by or arise from the dysfunction of condensates has provided new possibilities for modulating the function of high-value targets previously deemed ‘undruggable,’ opening unexplored avenues to identify hundreds of novel therapeutic targets. Dewpoint’s proprietary AI/ML-powered state-of-the-art platform underlies a drug discovery pipeline that spans multiple therapeutic areas, including oncology, neurodegenerative, cardiopulmonary, and metabolic diseases. Through collaborations with Bayer, Novo Nordisk, and Evotec, Dewpoint pushes the boundaries to accelerate the translation of condensate biology into medicine for patients suffering from difficult-to-treat diseases. Learn more at Dewpointx.com.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com.

The post Bayer and Dewpoint Therapeutics sign Licensing Agreement for Heart Disease Program appeared first on Dewpoint Therapeutics.

Poster presented at the 2024 Annual NEALS Meeting

> Download the PDF file

The post TDP-43 condensate modulation rescues TDP-43 loss of function in ALS patient-derived motor neurons and mouse models of TDP-43 proteinopathy appeared first on Dewpoint Therapeutics.

In June 2024, Lis Leiderman, M.D., MBA joined Dewpoint’s Executive Leadership Team as Chief Financial and Corporate Development Officer. With her unique experience as both a medical doctor and an experienced financial leader, she is dedicated to furthering our goal of bringing our groundbreaking therapeutics to the clinic and ultimately to improve the lives of patients. After four months in her new role, she shares her impressions of our science and our culture and her thoughts on the potential for Dewpoint’s future success. 

As a physician, Lis’ true passion is making a difference for patients, and she was looking for a position where she could do just that. She was initially intrigued by the Chief Financial Officer and Corporate Development Officer role at Dewpoint, because she saw the incredible potential that our pioneering and innovative science could have. “We really have the ability to change the treatment paradigm for many patients,” she says, “which is at the heart of why I do this work.”  

From the leadership team to scientists to members of the Finance team during her interview process, Lis saw that same passion and dedication to changing patients’ lives. “Everyone on our team is brilliant and driven,” she says. “We have some of the brightest, most respected scientists in the world, but at the same time they are humble and curious. They are just the kind of individuals that I could see myself working and partnering with. I wanted to join Dewpoint to make a difference and help the company evolve and become more mature to get to that next stage.” 

Revolutionary Science and a Visionary Culture  

Four months after joining the team, Lis sees that her initial impressions of Dewpoint rang true. “I absolutely made the right choice to join the company,” says Lis.  

The more she learns about condensate biology, the more inspired she is about how our science is going to change the world and the way that patients are treated. “What we’re doing is entirely differentiated; we are pushing boundaries and challenging traditional approaches,” she says. “And that just really excites me.” 

Not only is our science a unique differentiator, it’s also the Dewpoint culture, which is driven by the Dewpoint team members who are inspired by the groundbreaking work they do each day.  Lis believes that the culture is equally as important as the science, and she sees the entire team live the Dewpoint values of integrity, inclusion, innovation and impact, from the leadership team throughout the organization. “We are a committed group that is passionate about a like-minded goal and making a positive impact on patients.”  

“The Dewpoint culture is visionary at its core,” says Lis. “We are caring and collaborative in a very open and honest and inclusive fashion, and there’s mutual respect across all levels. People feel valued and know that their work means something.” 

Looking forward to the future  

With our revolutionary science and extraordinary team, Lis sees a bright future for Dewpoint, including in therapeutic areas and opportunities beyond even what we are doing today. She looks forward to working with her team to build additional partnerships and raise capital to continue to show the world what our science is capable of. “I’m inspired for what’s next,” she says. “We’re surrounded by so many people who believe in Dewpoint, including our board and our investors, who are exhilarated to see where our company goes.” 

The post Early Impressions from Dr. Lis Leiderman: “Dewpoint has the Potential to Change the World”  appeared first on Dewpoint Therapeutics.